Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma

NCT00556205 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Toxicity of combination from other trials

Conditions

Renal Cell Carcinoma

Interventions

DRUG: Sunitinib
DRUG: Bevacizumab

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]
[object Object]